{rfName}
Co

Indexed in

License and use

Citations

3

Altmetrics

Grant support

This study was partially supported by grants: the European Commission (grants: H2020-SC1-2016-RTD, Proposal: 731626), the Spanish Ministry of Economy (MINECO) (grants: SAF2015-66193-R, RTI2018-096309-B-I00, EC10-153, TRA-094), the Fondo de Investigacion Sanitaria (FIS) (PI15/00480, AC16/00051, and PI18/00699), the Fondo Europeo para el Desarrollo Regional (FEDER), the SPANISH AIDS Research Network RD16/0025/0002-ISCIII-FEDER (RIS), and the CERCA Programme/Generalitat de Catalunya (SGR 615). F.G. has received the support of Jose Maria Segovia de Arana contracts. HIVACAT: HIV development program in Catalonia. IDIBAPS: Institut d'Investigacions Biomediques August Pi I Sunyer.

Analysis of institutional authors

Fernandez Gaspart, IvetteAuthorPlana, Maria TeresaAuthorFernández IAuthorUgarte AAuthorEtcheverry FAuthorPich JAuthorArnaiz JaAuthorPlana MAuthorGarcia FCorresponding AuthorLeal LAuthor
Share
Publications
>
Article

Comparison of Safety and Vector-Specific Immune Responses in Healthy and HIV-Infected Populations Vaccinated with MVA-B

Publicated to:Vaccines. 7 (4): E178- - 2019-12-01 7(4), DOI: 10.3390/vaccines7040178

Authors: Couto, Elvira; Diaz-Brito, Vicenc; Mothe, Beatriz; Guardo, Alberto C; Fernandez, Irene; Ugarte, Ainoa; Etcheverry, Flor; Gomez, Carmen E; Esteban, Mariano; Pich, Judit; Arnaiz, Joan Albert; Lopez Bernaldo de Quiros, Juan Carlos; Brander, Christian; Plana, Montserrat; Garcia, Felipe; Leal, Lorna

Affiliations

CSIC, Ctr Nacl Biotecnol, Dept Mol & Cellular Biol, Campus Cantoblanco, Madrid 28049, Spain - Author
Hosp Badalona Germans Trias & Pujol, Irsicaixa AIDS Res Inst HIVACAT, Badalona 08916, Spain - Author
Hosp Clin Barcelona, Clin Trial Unit, Barcelona 08036, Spain - Author
Hosp Gregorio, Dept Infect Dis, Madrid 28009, Spain - Author
Parc Sanitari St Joan de Deu, Infect Dis Unit, St Boi De Llobregat 08830, Spain - Author
Univ Barcelona, Hosp Clin HIVACAT, Dept Infect Dis, IDIBAPS, E-08036 Barcelona, Spain - Author
Univ Barcelona, Hosp Clin, AIDS Res Grp, Retrovirol & Viral Immunopathol,IDIBAPS, E-08036 Barcelona, Spain - Author
See more

Abstract

There are few studies comparing the safety and immunogenicity of the same HIV immunogen in healthy volunteers and HIV-infected individuals. We analyzed demographics, adverse events (AEs), and immunogenicity against vaccinia virus in preventive (RISVAC02, n = 24 low-risk HIV-negative volunteers) and therapeutic (RISVAC03, n = 20 successfully treated chronically HIV-1-infected individuals) vaccine phase-I clinical trials that were performed with the same design and the same immunogen (modified vaccinia virus Ankara-B: MVA-B). Total AEs were significantly higher in HIV-infected patients (mean AEs/patient 6.6 vs. 12.8 (p < 0.01)). Conversely, the number of AEs related to vaccination (AEsRV) was similar between both groups. No grade III or IV AEsRV were observed in either clinical trial. Regarding the immunogenicity, the proportion of anti-vaccinia virus antibody responders was similar in both studies. Conversely, the magnitude of response was significantly higher in HIV-infected patients (median binding antibodies at w8 267 vs. 1600 U/mL (p = 0.002) and at w18 666 vs. 3200 U/mL (p = 0.003)). There was also a trend towards higher anti-vaccinia virus neutralizing activity in HIV-infected individuals (proportion of responders 37% vs. 63% (p = 0.09); median IC50 32 vs. 64 (p = 0.054)). This study confirms the safety of MVA-B independent of HIV serostatus. HIV-infected patients showed higher immune responses against vaccinia virus.

Keywords
dnahiv-1immunogenicitymva-bpoxvirus vectorspreventivetherapeuticDnaHiv-1Hiv-1-infected patientsImmunogenicityMva-bPoxvirus vectorsPreventiveTherapeuticVaccine

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Vaccines due to its progression and the good impact it has achieved in recent years, according to the agency Scopus (SJR), it has become a reference in its field. In the year of publication of the work, 2019, it was in position , thus managing to position itself as a Q1 (Primer Cuartil), in the category Pharmacology. Notably, the journal is positioned above the 90th percentile.

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2025-05-22:

  • WoS: 1
  • Scopus: 1
  • Europe PMC: 1
  • OpenCitations: 1
Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-05-22:

  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 16 (PlumX).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.
Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (Couto E) and Last Author (Leal Alexander, Lorna).

the author responsible for correspondence tasks has been Garcia Alcaide, Felipe.